<DOC>
	<DOCNO>NCT01056705</DOCNO>
	<brief_summary>Based pre-clinical trial phase 1 clinical data principle GCP , objective phase Ⅱ clinical trial evaluate safety immunogenicity Inactivated Poliomyelitis Vaccine make Sabin Strains ( Sabin IPV ) .</brief_summary>
	<brief_title>The Clinical Trial Protocol Inactivated Poliomyelitis Vaccine Made From Sabin Strains ( IPV )</brief_title>
	<detailed_description>The Sabin IPV manufacture poliovirus type1 , 2 , 3 Sabin strain Vero cell microcarrier culture 550 liter bioreactors . The virus suspension harvest , ultra-concentrated , purified inactivate formalin . Three formulation A , B , C Sabin IPV use , DAg content A type1 45 , type2 64 , type3 67.5 DU /0.5ml/per dose ; B 30,32,45 DU/0.5ml/per dose ; C 15,16,22.5 DU/0.5ml/per dose . Oral Poliomyelitis Vaccine ( OPV ) manufacture Institute Medical Biology , Chinese Academy Medical Sciences.Trivalent OPV contain Polioviruses Type 1 6.0 log CCID Type 2 5.0 log Type 3 5.5log /0.1ml/per dose Inactivated Poliomyelitis Vaccine ( Salk strain ) manufacture Sanofi Pasteur DAg content /0.5ml/per dose Type 1 40 DU , Type 2 8DU , Type 3 32DU . This randomized , blind phase 2 clinical trial . Total 500 infant ( age 60 day 90 day ) select , randomize five group ( group n=100 ) Sabin IPV formulations A , B , C , OPV , Salk IPV separately give group three dose one month apart respectively .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males female , age 60 day 90 day ; Adults , parent ( ) guardians able understand sign inform consent participation ; Participants guardians able attend plan clinical appointment obey follow study instruction ; Infants vaccinate poliovaccine preventive biologicals recent 7 day ; Axillary temperature ≤37℃ . Have medical record participant family allergy , convulsion , fall sickness , encephalopathy psychopathy ; Low platelet bleed disorder allow vaccination muscle ; Have damage low immunological function ; Received blood , plasma immunoglobulin treatment since birth ; Have inborn abnormality , develop obstacle clinical diagnostic serious chronic ( Down Syndrome , diabetes , sickle cell anemia neural GuillainBarre Syndrome ) ; Have doubtful following disease : respiratory system diseases , acute infection active chronic , cardiovascular disease , liver kidney disease , skin disease , HIV . Exclusion Criteria dose 2 3 Have serious anaphylaxis high fever , convulsion first dose ; Have circus Exclusion Criteria Eligible study ; Have serious adverse event relate previous vaccination ; Withdrawal Discontinuance Criteria ; Received necessary interference study drug : immuneinhibition immunestimulating agent ; Vaccinated vaccine（except DTP） ; Stop observation determine investigator owe occur serious adverse event ;</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>90 Days</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Inactivated Poliomyelitis Vaccine</keyword>
	<keyword>Sabin Strains</keyword>
	<keyword>poliomyelitis</keyword>
</DOC>